Treatment of obesity: medical managements
Keywords:
Overweight, Obesity, Body mass index, Weight loss, Pharmacotherapy, Orlistat, Rimonabant, Bariatric surgeryAbstract
Obesity is a very complex illness. It is one of the most prevalent diseases in the western world, its importance lies in the comorbidities that surround it, as well as the predisposition to cardiovascular events and other diseases that reduce life quality and expectancy. There are many factors that contribute to obesity pathogenesis; genetic, psychological, emotional, social factors, among others. Nowadays dietetic measures and changes in lifestyle are the first step in management of obesity. Because in many cases it is not enough for patients to reach their ideal weight, pharmacotherapy must be used to treat obesity and its comorbidities. Several studies have compared various drugs for losing weight, being Orlistat the only one approved by the FDA. In bariatric surgery, many surgical techniques have been developed to try to reach a balance between efficacy and safety. Although it is relatively safe, it has its own risks inherent to the procedure and its complications. It is the most effective measure to improve the global patients’ health as it not only helps people to lose weight, but also helps to have a better control of other comorbidities and lower overall mortality.
References
Aballay, L.R., Osella, A.R., Celi, A., Díaz, M.P., 2009. Overweight and obesity: Prevalence and their association with
some social characteristics in a random sample population –based study in Córdoba city, Argentina. Obes.
Res. Clin. Pract. 3,75-83.
Aronne, L.J., Thornton-Jones, Z.D., 2007. New targets for obesity pharmacotherapy. Clin. Pharmacol. Ther. 81,748-
Ballinger, A., Peikin, S.R., 2002. Orlistat: its current status as an antiobesity drug. Eur. J. Pharmacol. 440,109-117.
Berthoud, H.R., 2004. Neural control of appetite: cross-talk between homeostatic and non-homeostatic systems.
Appetite. 43,315-7.
Bray, G.A., 2008. Medications for Weight Reduction. Endocrinol. Metab. Clin. North Am. 37,923-42.
Buchwald, H., Avidor, Y., Braunwald, E., Jensen, M.D., Pories, W., Fahrbach, K., 2004. Bariatric surgery: a systematic
review and meta-analysis. JAMA. 292,1724-37.
Chen, H., Morris, M.J., 2007. Maternal smoking – A contributor to the obesity epidemic? Obes. Res. Clin. Pract.
,155-63.
Dodd, M., 2008. Obesity and time-inconsistent preferences. Obes. Res. Clin. Pract. 2,83-9.
Erlanger, S., Henson, E., 2008. Classification and Pharmacological Management of Obesity. P T. 33,724-8.
Filippatos, T.D., Derdemezis, C.S., Gazi, I.F., Nakou, E.S., Mikhailidis, D.P., Elisaf, M.S., 2008. Orlistat-Associated
Adverse Effects and Drug Interactions: A Critical Review. Drug Saf. 31, 53-65.
Flum, D.R., Belle, S.H., King, W.C., Wahed, A.S., Berk, P., 2009. Perioperative safety in the longitudinal assessment
of bariatric surgery. N. Engl. J. Med. 361,445-54.
Hainer, V., Toplak, H., Mitrakou, A., 2008. Treatment modalities of obesity: what fits whom? Diabetes Care Suppl.
, S269-77.
Halford, J.C., 2006. Pharmacotherapy for obesity. Appetite. 46,6-10.
Hampp, C., Hartzema, A.G., Kauf, T.L., 2008. Cost-utility analysis of rimonabant in the treatment of obesity. Value
Heal. 11,389-99.
Hollander, P.A., Elbein, S.C., Hirsch, I.B., Kelley, D., McGill, J., Taylor, T., 1998. Role of Orlistat in the Treatment of
Obese Patients With Type 2 Diabetes. A 1year randomized double-blind study. Diabetes Care. 21,1288-94.
Hsieh, C.J., Wang, P.W., Liu, R.T., Tung, S.C., Chien, W.Y., Chen, J.F., 2005. Orlistat for obesity: benefits beyond
weight loss. Diabetes Res. Clin. Pract. 67,78-83.
Isidro, M.L., Cordido, F., 2009. Drug Treatment of Obesity: Established and Emerging Therapies. Mini. Rev. Med.
Chem. 9,664-73.
Keightley, J., Chur-Hansen, A., Princi, R., Wittert, G., 2011. Perceptions of obesity in self and others. Obes. Res. Clin.
Pract. 5,341-9.
Lam, D.D., Przydzial, M.J., Ridley, S.H., Yeo, G.S., Rochford, J.J., O'Rahilly, S., 2008. Serotonin 5-HT2C receptor
agonist promotes hypophagia via downstream activation of melanocortin-4 receptors. Endocrinol. 149,1323–
Levy, R.L., Finch, E.A., Crowell, M.D., Talley, N.J., Jeffery, R.W., 2007. Behavioral Intervention for the Treatment of
Obesity. Am. J. Gastroenterol. 102, 2314-21.
Limbers, C.A., Turner, E.A., Varni, J.W., 2008. Promoting healthy lifestyles: Behavior modification and motivational
interviewing in the treatment of childhood obesity. J. Clin. Lipidol. 2,169-78.
Mechanick, J.I., Kushner, R.F., Sugerman, H.J., Gonzalez-Campoy, J.M., Collazo-Clavell, M.L., Guven, S., 2008.
American Association of Clinical Endocrinologists, the Obesity Society, and American Society for Metabolic &
Bariatric Surgery Medical Guidelines for clinical practice for the perioperative nutritional, metabolic, and
nonsurgical support of the bariatric surgery patient. Surg. Obes. Relat. Dis. 4(5 Suppl),S109-84.
Nakamura, M., Tanaka, M., Abe, S., Itoh, K., Imai, K., Masuda, T., 2000. Association between beta 3-adrenergic
receptor polymorphism and a lower reduction in the ratio of visceral fat to subcutaneous fat area during
weight loss in japanese obese women. Nutr. Res. 20, 25-34.
Neff, L.M., Aronne, L.J., 2007. Pharmacotherapy for obesity. Curr. Atheroscler. Rep. 9,454-62.
Poortinga, W., Gebel, K., Bauman, A., Moudon, A.V., 2011. Neighborhood Environment, Physical Activity and
Obesity. Encyclopedia. Env. Heal. 1,44-53
Scheen, A.J., Finer, N., Hollander, P., Jensen, M.D., Van Gaal, L.F., RIO-Diabetes, S.G., 2006. Efficacy and tolerability
of rimonabant in overweight or obese patients with type 2 diabetes: a randomized controlled study. Lancet.
,1660–72.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2012 R. Bolaños-Jímenez, J. Arizmendi-Vargas, S. Salazar-Marioni, C.E. Escamilla-Ocañas, K. Lozano-Andrade, H.R. Martínez-Menchaca, G. Rivera-Silva
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
